Incannex IHL.AX (ASX) 03 Feb 2026 A$0.041, 61,360,016 vol: watch clinical catalysts

IHL.AX stock was one of the ASX’s most active names on 03 Feb 2026, closing at A$0.041 after 61,360,016 shares changed hands. The price fell 10.87% from yesterday’s close of A$0.046, driven by heavy volume and profit-taking around recent trial updates. Traders and investors are watching Incannex Healthcare Limited (ASX) for upcoming clinical readouts and cash runway updates that could move the stock.

Why IHL.AX stock was most active today

Trading volume in IHL.AX reached 61,360,016 shares, nearly ten times the average volume of 6,427,691. This surge made Incannex Healthcare Limited one of the day’s top active ASX stocks. The large volume accompanied a price drop to A$0.041, suggesting distribution by short-term holders.

Clinical pipeline and news driving IHL.AX stock

Incannex’s portfolio includes Phase IIa assets such as IHL-42X and Psi-GAD and several Phase IIa dermatology programs. Market reaction today reflects investor focus on trial milestones and the company’s limited commercial revenue base. For direct company disclosures see the official investor site Incannex Healthcare and ASX company page ASX: IHL.

IHL.AX stock valuation and financial snapshot

Incannex closed with a market capitalisation of A$14,255,927 and 347,705,540 shares outstanding. The company reports EPS of -1.30 and a negative PE. Key valuation metrics: price to book 0.75, price to sales 14.06, and cash per share A$0.0217. These figures show a biotech-style loss-making profile with a strong current ratio of 9.02, offering liquidity but limited revenue.

Technicals and trading levels for IHL.AX stock

Short-term trend is weak. IHL.AX closed below its 50-day average of A$0.0649 and its 200-day average of A$0.10285. The intraday range was A$0.041 to A$0.051. High relative volume (relVolume 9.55) indicates elevated interest that could accelerate moves if catalysts arrive.

Meyka grade and model forecast for IHL.AX stock

Meyka AI rates IHL.AX with a score out of 100: 60.99 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a base-case price target of A$0.080 within 12 months. Compared to the current price of A$0.041, that implies an upside of 95.12%. Forecasts are model-based projections and not guarantees.

Risks and catalysts affecting IHL.AX stock outlook

Primary risks include continued negative earnings, trial setbacks, and dilution from capital raises. Key catalysts are Phase II readouts, regulatory updates, and funding announcements. Sector context: healthcare peers trade at an average PE of 22.40 and PB of 1.33, highlighting IHL.AX’s early-stage risk profile and lower PB of 0.75.

Final Thoughts

IHL.AX stock closed the ASX session at A$0.041 on 03 Feb 2026 after a heavy 61,360,016 share turnover and a 10.87% decline. The move reflects active trading around clinical timelines rather than changes to commercial revenue. Our valuation view emphasises the binary nature of small-cap biotech risk and potential. Meyka AI’s base-case forecast of A$0.080 implies a 95.12% upside, while a conservative downside target of A$0.030 implies -26.83% from today’s price. Investors should weigh the pipeline catalysts and cash runway against the company’s loss-making profile, negative EPS of -1.30, and reliance on future trial success. For ongoing updates and intraday signals see the Meyka stock page for IHL.AX on our platform IHL.AX on Meyka. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.